Post-approval studies (Phase 4)WithdrawnNCT04143958
What this trial is testing
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Who this might be right for
Fabry Disease
Sanofi